NCCN 2014 guideline already stated that Pertuzumab-based regimen is the new standard of care for HER2-positive metastatic or locally recurrent/unresectable breast cancer patients who have not yet received previous anti-HER2 therapy or chemotherapy for their metastatic/recurrent/unresectable disease.